Abstract
Objective—To evaluate the long term results of coronary reoperations for recurrent angina with internal mammary arteries versus vein grafts.
Design—Inception cohort of 103 patients with a mean follow up of 7.1 years (range 1.0–11.6).
Setting—Regional cardiothoracic centre.
Patients—Among 103 consecutive patients, mean (SD) age 61.8 (9.7) years, who were reoperated for recurrent angina between January 1982 and December 1991, 53 patients had unilateral or bilateral internal mammary artery (IMA) grafting supplemented or not with saphenous vein (SV) grafts (group A), and 50 patients underwent reoperative coronary surgery using SV grafts only (group B). The two groups were comparable in terms of demographic and clinicopathological data.
Measurements and results—Operative mortality was 5.6% (95% confidence interval 4.6 to 6.6) for group A, and 10% (8.2 to 11.8) for group B (p > 0.05). Probability of freedom from new recurrence of angina was 86% at 5 and 10 years in group A, compared with 56% and 25% respectively in group B (p = 0.005). Freedom from cardiac events was estimated to be 81% at 5 and 10 years in group A, v 52% and 20% for group B, respectively. Actuarial survival was 95% v 93% at 3 years, 95% v 85% at 5 years, and 88% v 71% at 10 years after reoperation (p > 0.05).
Conclusions—The long term results of IMA are superior to SV grafts in terms of freedom from new recurrence of angina and other cardiac events. The IMA is thus the conduit of choice in coronary revascularisation.

Keywords: coronary artery bypass; coronary reoperation; recurrent angina; internal thoracic (mammary) artery

During the past 20 years in coronary artery surgery, the most important development has been the employment of the internal mammary artery (IMA) as a conduit. The IMA has been found to be a superior conduit in first time coronary artery bypass grafting (CABG); compared with vein conduits, it has significantly reduced hospital mortality and probability of coronary reoperation. Furthermore, when reoperation is indicated because of the failure of other grafts or progressive atherosclerosis, a patent IMA does not increase the risk of reoperation and additional IMA grafting at reoperation does not increase the hospital morbidity or early mortality.

Although most surgeons appreciate that the IMA is the conduit of choice in the primary operation, there is reluctance to use IMA grafts in reoperations (which play an increasing role in coronary artery surgery) on patients in whom neither IMA, or only one, was used at the first operation. Previous studies have addressed the efficacy and role of IMA grafts in repeat CABG, but there is still limited documentation of the long term results—at 10 years—by means of actuarial survival and event-free probability. In this report, we compare the early and late results of IMA versus saphenous vein grafting in reoperations for recurrent angina, and concentrate on the freedom from cardiac events, long-term survival, and the probability of further recurrence of angina after a successful second operation.

Methods
Between January 1981 and December 1990, 103 consecutive patients with recurrent angina after previous coronary grafting underwent repeat myocardial revascularisation procedures performed under the care of one surgeon (AHB). There were 82 men and 21 women, none having had an IMA graft at the primary operation. Their mean (SD) age was 61.8 (9.7) years, range 43 to 71.

The patients were divided into two groups according to whether, at reoperation, an IMA graft was used as a conduit. Group A consisted of 53 patients (51%), mean age 59.8 (10.8) years, submitted to unilateral (40 (75%)) or bilateral (13 (25%)) IMA grafting, supplemented or not with saphenous vein (SV) grafts; group B comprised 50 patients (49%), mean age 63 (8.8) years, who had only SV grafts.

Demographic and clinicopathological data, and predisposing factors for both groups are given in tables 1 and 2. After reviewing the angiographic data, the causes of reoperation in groups A and B, respectively, were as follows: patent atherosclerotic (stenotic) vein graft disease in 37% and 46%, graft blockage in 33% and 22%, and progression or new native disease in 28% and 30%. Triple vessel disease was identified in 64% and 60% respectively. The mean time elapsed between first operation and angina recurrence was 57.3 months for group A and 61.4 months for group B. The
The distribution of demographic and clinicopathological characteristics of the two groups of patients is shown in Table 1. There were no significant differences between the groups with respect to other demographic and clinicopathological data. Thus the groups were considered compatible for the rest of our analyses.

**Table 1: Distribution of demographic and clinicopathological characteristics of the two groups of patients**

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Group A (n = 50)</th>
<th>Group B (n = 50)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>60.8 (10.8)</td>
<td>63 (8.8)</td>
<td>0.10</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>43</td>
<td>39</td>
<td>0.69</td>
</tr>
<tr>
<td>Female</td>
<td>10</td>
<td>11</td>
<td></td>
</tr>
<tr>
<td>Angina-free interval after 1st CABG (months)</td>
<td>57.3 (18)</td>
<td>61.4 (24)</td>
<td>0.37</td>
</tr>
<tr>
<td>Time from 1st to 2nd operation (months)</td>
<td>61.2 (23.4)</td>
<td>65.4 (32)</td>
<td>0.17</td>
</tr>
<tr>
<td>Left ventricular function</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Good</td>
<td>30 (57)</td>
<td>20 (40)</td>
<td>0.09</td>
</tr>
<tr>
<td>Poor</td>
<td>16 (30)</td>
<td>19 (38)</td>
<td>0.40</td>
</tr>
<tr>
<td>Left main disease</td>
<td>7 (13)</td>
<td>6 (12)</td>
<td>0.34</td>
</tr>
<tr>
<td>Triple vessel disease</td>
<td>34 (64)</td>
<td>36 (64)</td>
<td>0.66</td>
</tr>
<tr>
<td>Urgent surgery</td>
<td>8 (15)</td>
<td>10 (20)</td>
<td>0.51</td>
</tr>
<tr>
<td>No of grafts at 1st operation</td>
<td>3.1 (1)</td>
<td>3.2 (1.2)</td>
<td>0.56</td>
</tr>
<tr>
<td>No of grafts at 2nd operation</td>
<td>2.8 (0.9)</td>
<td>3 (1.1)</td>
<td>0.34</td>
</tr>
<tr>
<td>Angiographic data</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Graft blockage</td>
<td>18 (33)</td>
<td>11 (22)</td>
<td>0.61</td>
</tr>
<tr>
<td>Atherosclerotic vein graft disease</td>
<td>20 (37)</td>
<td>23 (46)</td>
<td>0.39</td>
</tr>
<tr>
<td>Progression/new disease</td>
<td>15 (28)</td>
<td>15 (30)</td>
<td>0.85</td>
</tr>
<tr>
<td>Incomplete revascularisation</td>
<td>1 (2)</td>
<td>1 (2)</td>
<td>0.73</td>
</tr>
</tbody>
</table>

Group A, IMA grafts (with or without SV grafts); group B, SV grafts only. Values are expressed as mean (SD), and number of patients (%). There were no significant differences between the groups.

**Table 2: Distribution of predisposing factors between the two groups of patients at the time of reoperation**

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Group A (n = 50)</th>
<th>Group B (n = 50)</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Smoking</td>
<td>8 (15)</td>
<td>7 (14)</td>
<td>0.87</td>
</tr>
<tr>
<td>Obesity</td>
<td>16 (30)</td>
<td>12 (24)</td>
<td>0.48</td>
</tr>
<tr>
<td>Hypertension</td>
<td>4 (7)</td>
<td>5 (10)</td>
<td>0.74</td>
</tr>
<tr>
<td>Hypertension/anaemia</td>
<td>4 (7)</td>
<td>4 (8)</td>
<td>0.93</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>3 (6)</td>
<td>5 (10)</td>
<td>0.48</td>
</tr>
<tr>
<td>Family history of ischaemic heart disease</td>
<td>17 (32)</td>
<td>16 (32)</td>
<td>0.99</td>
</tr>
</tbody>
</table>

Group A, IMA grafts (with or without SV grafts); group B, SV grafts only. Values are expressed as number of patients (%). There were no significant differences between the two groups.

Early Results

Mortality

There were three deaths in group A, and five in group B. For the entire population, the overall hospital mortality (30 day mortality, or at any time if the patient remained in hospital more than 30 days) was 7.8% (95% CI 6.4 to 9.2); 5.6% (4.6 to 6.6) for group A and 10% (8.2 to 11.8) for group B (p < 0.05). In group A, the causes of death were perioperative myocardial infarction in two patients and acute traumatic dissection of the right internal mammary artery in one. The causes of death in the patients in group B were myocardial infarction and low cardiac output state in three, postoperative stroke in one, and pulmonary sepsis following prolonged ventilation for respiratory failure in one.

Morbidity

Table 3 summarises the postoperative complications. Perioperative myocardial infarction occurred in 6% of the patients in the IMA group and in 14% in the SV group. Reopening for bleeding was required in 8% and 4%, respectively, while wound complications developed in three patients and one patient, respectively. None of the differences in the morbidity rate between the two groups was significant, although wound complications and postoperative bleeding were observed more often in the IMA group, while the incidence of myocardial infarction was higher in the SV group.

**Statistical Analysis**

Dichotomous variables are expressed as numbers of patients and continuous variables as means (SD). Comparisons between the two groups were made with the t test, the χ² test, and Fisher’s exact test as required. Actuarial and event-free survival figures were obtained by the Kaplan-Meier product-limit method. Comparisons were made by the log-rank test, using the Biomedical Data Processing statistical package. Ninety-five per cent confidence intervals (95% CI) were calculated for mortality, event-free, and actuarial survival rates. Probability (p) values < 0.05 were considered significant.

**Results**

**Group Compatibility**

Although patients receiving IMA grafts tended to be younger (mean age 59.8 ± 63 years), this difference was not significant (0.1 > p > 0.05). There was also no significant difference between the two groups with respect to other demographic and clinicopathological data. Thus the groups were considered compatible for the rest of our analyses.
For the entire study population, the 3, 5, and 10 year figures for freedom from recurrent angina were 71%, 71%, and 54%, respectively (fig 1A; table 4). However, the probability of freedom from recurrent angina in the patients in group A was estimated at 86% at 3, 5, and 10 years, as compared with 56%, 56%, and 25% for those in group B (fig 1B; table 4). This difference was highly significant (p = 0.005).

**Event-free analysis**

Overall freedom from cardiac events (including further recurrent angina, death, and subsequent myocardial revascularisation procedure or heart transplant) was estimated at 67%, 67%, and 50% at 3, 5, and 10 years after the second operation (fig 2A; table 4). For group A, this was 81% at 3 and 5 years, compared with 52% and 20% for group B (fig 2; table 4). Patients having IMA grafting at reoperation had a greatly increased probability of freedom from cardiac events (p = 0.0009).

**Late survival**

For the entire group, the overall late survival rates among the operative survivors were 91%, 88%, and 80% at 3, 5, and 10 years after reoperation (fig 3; table 4). Survival was 95% for group A v 93% for group B at 3 years, 95% v 85% at 5 years, and 88% v 71% at 10 years, respectively. Although late survival was better for patients receiving IMA grafts at reoperation, this difference did not reach significance (fig 3B; table 4).

**Discussion**

Reoperation for coronary artery disease has become a standard procedure, accounting for approximately 6% to 10% of all coronary bypass operations performed annually. For those surviving up to 15 years after CABG, the incidence of reoperation approaches 38%, and the main cause of reintervention is the development of vein graft atherosclerosis.

Despite an increased operative mortality and a possibly decreased postoperative benefit, it has been well documented that reoperation is a safe and appropriate strategy that improves the survival of patients with late vein graft stenoses, and gives satisfactory symptomatic improvement.
There is no doubt that the internal mammary artery is a durable biological conduit for myocardial revascularisation. In a 15 year follow up of patients who underwent IMA grafting at primary operation, Cameron and colleagues found that IMA grafting reduced the risk of dying by a factor of 0.73, and was a significant predictor of late survival. The IMA graft is therefore a powerful surgical tool and should not be withheld from any subgroup of patients, including those undergoing reoperation. We started using bilateral IMA conduits in reoperations, complemented with SV grafts, in 1984. During the latter years of this study period, IMA grafting has become our surgical technique of choice.

In this report, we compared the long term results of IMA versus SV grafts in two otherwise homogeneous and statistically compatible groupsof patients requiring reoperation between 1981 and 1991. The overall operative mortality was 7.8%, and perioperative myocardial infarction was the most common severe complication. Others have reported a reoperative mortality rate ranging from 3.7% to 13% in the presence of patent atherosclerotic vein grafts. It is notable that our operative mortality tended to be lower in patients receiving an IMA graft (5.6%) than in those having SV grafts only (10%, p > 0.05). This probably reflects the increasing experience with IMA grafting in reoperations during the latter years of our study.

Despite the relatively small sample of patients—which represents a potential limitation of our study—we were able to show that, in reoperations, the long term results of IMA grafts were superior to SV grafts, as has been shown with primary operations. Freedom from cardiac events was 81% at 5 and 10 years following reintervention, compared to 52% and 20% in SV grafts group (p = 0.0009). Furthermore, freedom from development of recurrent angina was significantly increased in the IMA group (86% at 5 and 10 years) compared with the SV group (56% and 25% respectively, p = 0.005). These results indicate that IMA grafting in reoperations substantially improves both early and late results.

Surprisingly, however, we failed to detect a significant difference in terms of late survival between the two groups; excluding in-hospital mortality, actuarial survival, although better (95% and 88% v 85% and 71% at 5 and 10 years, respectively), failed to reach significance. Nevertheless, a similar observation has been recently reported by Galbut et al. They evaluated 88 patients who underwent coronary bypass reoperations with bilateral IMA grafts, and 88 computer matched patients receiving SV grafts, and observed a 91.6% v 85.3% survival at 5 years (NS). Thus the pattern of long term survival was similar in the two groups.

It has been postulated in the past that patients undergoing coronary reoperations have less relief of angina than patients having primary revascularisation. Loop reported an approximately 50% rate of recurrent angina 10 years after reoperative surgery in a large series of patients. Similarly, Cameron and colleagues reported that 66% of such patients had recurrent angina, compared with 35% of patients with primary revascularisation followed up to 5 years. In contrast, this study showed a substantially better result in terms of angina

Figure 2 (A) Kaplan-Meier product probability of freedom from cardiac events for the entire population study. (B) Comparison between the internal mammary artery and saphenous vein groups of patients. IMA, internal mammary artery; SVG, saphenous vein graft. Numbers of patients at risk are also shown.

Figure 3 (A) Actuarial (Kaplan-Meier) survival for the entire population study. (B) Comparison of survival between the internal mammary artery and saphenous vein groups of patients. IMA, internal mammary artery; SVG, saphenous vein graft. Numbers of patients at risk are also shown.
relief at 10 years from reoperation when one or both IMAs were used, alone or in conjunction with supplementary SV grafts. In addition, we have previously shown that only for those relatively young patients undergoing IMA grafting at reoperation does second time CABG become a cost-effective procedure, enabling patients to return to work.

The frequency of reoperations for clinically symptomatic patients is increasing in particular among those who had no arterial grafts at primary surgery. There are some situations in which reoperation with IMA grafts is not recommended: patients with radiation induced atherosclerosis; those with extensive brachiocephalic atherosclerosis including the aorta and the innominate, carotid, and proximal subclavian systems, which may also cause a subclavian steal phenomenon; those with patent large diameter, atherosclerotic vein grafts, the replacement of which with smaller diameter IMA might result in hypoperfusion; and those whose IMA grafts were damaged during the primary operation or who suffered severe wound infection and mediastinitis. As the sternal blood supply in patients with diabetes is not compromised, diabetes should not be considered an absolute contraindication to the use of IMA grafting at reoperation. In the absence of either internal mammary artery, the use of another arterial conduit must be considered, such as the right gastroepiploic artery, the inferior epigastric artery, or the radial artery.

In conclusion, our study showed that compared with SV grafts, the use of IMA grafts in reoperative coronary surgery is associated with lower early mortality and a significantly increased interval before recurrence of cardiac events or angina. We recommend, therefore, the use of the IMAs as the conduit of choice in reoperations for myocardial revascularisation.

1 Dargie HJ. Late results following coronary artery bypass grafting. Eur Heart J 1992;13(suppl II):89–95.